Equity · Healthcare
CNMD
NYSEConmed (CNMD)
The line runs 46.34 USD on 11 September through 51.17 USD on 10 November, on a scale from 40 to 55. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.5B USD
- P/E (TTM)
- 33.9
- Revenue, year to Dec 2025
- 1.4B USD
- EPS, diluted, year to Dec 2025
- 1.51 USD
- 52-week range
- 32 USD – 53.69 USD
- Avg volume
- 23.5K
as of Nov 10, 2026
Have Conmed (CNMD) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, no Conmed insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 11 Nov 2026, newest Form 4 filing 4 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Foust Hollie KGeneral Counsel & Corp Sec | Option exercise | 4,000 | |
| 04 Nov 2026 | Foust Hollie KGeneral Counsel & Corp Sec | Tax withheld | 1,124 | 60K USD |
| 08 Sep 2026 | Kelderman KimDirector | Option exercise | 500 |
Which funds hold Conmed (CNMD)?
9 of the 45 institutional funds we track reported a Conmed position for the quarter ended 30 Jun 2026 — a combined 54.3M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 728,976 | 23.9M USD | −6.8% |
| AQR Capital Management | Added | 280,916 | 9.2M USD | +250.1% |
| Marshall Wace | Held (±25%) | 175,454 | 5.7M USD | +2.8% |
| Citadel Advisors | Trimmed | 142,263 | 4.7M USD | −42.4% |
| Millennium Management | Added | 114,609 | 3.8M USD | +51.0% |
| Point72 Asset Management | Trimmed | 69,585 | 2.3M USD | −48.1% |
| D. E. Shaw & Co. | Added | 68,134 | 2.2M USD | +42.4% |
| GAMCO Investors | Held (±25%) | 57,200 | 1.9M USD | |
| Tudor Investment Corp | New position | 23,303 | 763K USD | |
| Balyasny Asset Management | Exited |
Have members of Congress traded Conmed (CNMD)?
The most recent congressional trade disclosed in Conmed is a purchase by David J. Taylor (house, OH), dated 15 Feb 2019.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 15 Feb 2019 | David J. Taylorhouse · Republican–OH | Purchase | 1K USD–15K USD | 27 days |
What has been filed or recorded for Conmed (CNMD)?
The filings we hold for Conmed, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 353 shares | 16K USD notional · 0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 808 shares | 36K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 658 shares | 31K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.66 USD | Revenue $336M |
| 30 Sep 2026 | Financials | Total assets | 2.3B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.1B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.77 USD | Revenue $343M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.51 USD | Revenue $1.37B |
| 31 Dec 2025 | Financials | Revenue | 1.4B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 47.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.51 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.09 USD | Revenue $338M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.69 USD | Revenue $342M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.19 USD | Revenue $321M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 4.25 USD | Revenue $1.31B |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS 1.57 USD | Revenue $317M |
What do people ask about Conmed (CNMD)?
What did Conmed shares close at?51.17
Conmed closed at 51.17 USD on 10 Nov 2026, down 1.56% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Conmed’s market cap?1.5B
Conmed is worth 1.5B USD by market value as of 10 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Conmed’s P/E ratio?33.9
Conmed has a price-to-earnings ratio of 33.9, as of 10 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Conmed’s revenue?1.4B
Conmed reported revenue of 1.4B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Conmed insiders bought or sold shares recently?3 filings
In the 90 days to 11 Nov 2026, no Conmed insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Conmed?9 of 45
9 of the 45 funds we track reported a Conmed position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, AQR Capital Management and Marshall Wace. See Funds
Have members of Congress traded Conmed?1 trade
Yes. 1 trade in Conmed appears in the congressional disclosures we hold: a purchase by David J. Taylor (House, OH) dated 15 Feb 2019, filed 14 Mar 2019. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Conmed last report earnings?0.66
Conmed last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.66 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. David J. Taylor: Ike Hayman, House Creative Services, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings